Renovo plc

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Renovo Group plc
Type Public limited company
(LSERNVO)
Headquarters Manchester, United Kingdom
Key people Mark Ferguson (CEO)
Website www.renovo.com

Renovo Group plc (LSERNVO) is a biopharmaceutical company, which was founded in 1998 and is headquartered in Manchester, United Kingdom. It works in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.[1] Renovo does not currently have any marketed products. It aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe"[2] in approximately 2014. As of 2011, it employs 10 people, although it once employed over 100.[3]

Renovo is listed on the London Stock Exchange and is a constituent of the FTSE Fledgling Index.

Products[edit]

Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two drugs in phase II clinical development, and numerous pre-clinical candidates.[4]

Drug Phase Action
Juvista Failed[5] Injected to the wound margins around the time of surgery causes a prevention or reduction of scarring through introduction of recombinant TGFβ3.
Adaprev Halted[6] Injected at the time of surgery for the prevention and reduction of scarring and adhesions between the tendon and surrounding tissues following tendon repair.].
Prevascar Halted[7] Injected to the wound margins around the time of surgery causes a reduction of scarring through suppression of TGFβ1 and TGFβ2.
Juvidex Renovo plans to partner Juvidex as a cosmetic ingredient for the improvement of skin appearance and to promote the healing of damaged skin.
RN1005 Phase I Clinical trial RN1005 is an advanced preclinical candidate pharmaceutical, discovered by Renovo, targeting the Wnt pathway to reduce scarring and enhance tissue regeneration.

Disambiguation[edit]

Renovo Group, PLC. has no affiliation with Renovo Neural, Inc. (www.renovoneural.com), a preclinical research organization founded in Cleveland, OH, USA, in 2008. Renovo Neural's business is focused on identifying and developing neural therapies for neurodegenerative diseases, including multiple sclerosis and Parkinson's Disease. [8]

References[edit]

External links[edit]